Skip to content

Amgen AMGN Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Nektar Therapeutics logo
Nektar TherapeuticsNKTR
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
AbbVie logo
AbbVieABBV
Roivant Sciences logo
Roivant SciencesROIV
Tango Therapeutics logo
Tango TherapeuticsTNGX

Other financials

Income statement

See full
Revenue$8.6B+5.8%
Gross profit$5.9B+13.4%
Operating income$2.7B+126%
Net income$1.8B+5.1%
EPS (diluted)$3.34+4.4%

Balance sheet

See full
Cash & equivalents$559.0M+10.0%
Total debt$57.3B-0.1%
Total equity$9.2B+48.1%
Total assets$92.5B+3.5%

Cash flow

See full
Operating cash flow$2.2B+57.4%
CapEx$712.0M+73.2%
Free cash flow$1.5B+50.7%

Valuation

See full
Market cap$195.44B+34.6%
Enterprise value$252.2B+25.7%
P/E25.1×+3.1×
P/S5.3×+1.1×

Profitability

See full
Gross margin68.3%+5.3pp
Operating margin28.4%+6.6pp
Net margin21%+3.6pp
FCF margin23.1%-8.9pp

Returns & leverage

See full
Return on equity101.3%-4.4pp
Debt / equity6.2×-3.0×
Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amgen's common stock, par value (in dollars per share)?
Amgen (AMGN) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
How has Amgen's common stock, par value (in dollars per share) changed year-over-year?
Amgen's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for Amgen's common stock, par value (in dollars per share)?
Over 5 years (2020 to 2025), Amgen's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.